837430-20-3

Usage

General Description

1,2,4-Triazolo[4,3-a]pyrazine, 5,6,7,8-tetrahydro-3-(2,2,2-trifluoroethyl)- is a chemical compound with the molecular formula C9H10F3N5. It is a derivative of the pyrazine class of compounds and contains a trifluoroethyl group. This chemical has potential applications in the pharmaceutical industry, specifically in the development of new drugs and medications. Its specific properties and potential uses would depend on further research and testing, but it shows promise as a building block for the synthesis of other compounds with potential therapeutic benefits. As with all chemicals, proper handling and safety precautions should be taken when working with 1,2,4-Triazolo[4,3-a]pyrazine, 5,6,7,8-tetrahydro-3-(2,2,2-trifluoroethyl)- to prevent any potential hazards.

Upstream product

• 837430-18-9 3-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[4,3-a]pyrazine 

Downstream Products

• 1026406-69-8 {1-(2,5-difluoro-benzyl)-3-oxo-3-[3-(2,2,2-trifluoro-ethyl)-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-propyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF

A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof.

PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF

A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof are described.

(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

A novel series of β-amino amides incorporating fused heterocycles, i.e., triazolopiperazines, were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (1) is a potent, orally active DPP-IV inhibitor (IC50 = 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclinical species, and in vivo efficacy in animal models. MK-0431, the phosphate salt of compound 1, was selected for development as a potential new treatment for type 2 diabetes.